REDLAMP 6: Entecavir vs. Lamivudine in Preventing Hepatitis B Reactivation in Untreated DLBCL

Reactivation of the Hepatitis B virus (HBV) can be a serious and life threatening complication for lymphoma patients who receive rituximab based treatment like R-CHOP. In this video Dr. Jia Ruan explained the results from a randomized phase 3 trial published in JAMA (The Journal of the American Medical Association). In this study researchers compared the effectiveness of Entecavir and lamivudine in preventing HBV reactivation and clinically significant hepatitis in patients with DLBCL, who are receiving R-CHOP.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 646-962-2074.

Author: lymphomaprogram

Located on the Upper East Side of New York City, the Lymphoma Program at Weill Cornell Medical College/NewYork Presbyterian Hospital is internationally recognized for our efforts to enable patients with non-Hodgkin lymphoma, Hodgkin disease and related disorders to have the best possible clinical outcome, including cure when possible. View all posts by lymphomaprogram